Home›Compare›Lemonaid Health vs Sprout Health

Lemonaid Health vs Sprout Health: Which Is Better?

Head-to-head comparison of Lemonaid Health and Sprout Health based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

Lemonaid Health scores higher overall in our independent evaluation (66.1/100 vs 50.9/100), leading on trust & safety, value, experience, product range, reputation.

A long-running, broad-scope telehealth generalist now operating under new nonprofit ownership following 23andMe's 2025 bankruptcy.

Visit Lemonaid Health
51
Sprout Health
Below Average

Sprout Health is an Encinitas, CA telehealth brand selling compounded semaglutide, tirzepatide and NAD+. It received an FDA warning letter in September 2025 and has an F rating from the BBB.

Visit Sprout Health

Score Breakdown

DimensionLemonaid HealthSprout Health
Overall Score66.1/100 ✓50.9/100
Trust & Safety30%62/100 ✓45/100
Value25%68/100 ✓62/100
Experience20%65/100 ✓48/100
Product Range15%80/100 ✓55/100
Reputation10%55/100 ✓40/100

At a Glance

Founded20132021
HeadquartersSan Francisco, CAEncinitas, CA
Publicly tradedNoNo
Treatment categories42
Treatments listed55
Starting price$10/mo$149/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryLemonaid HealthSprout Health
Weight Loss / GLP-1$129–$399
GLP-1 Weight Loss Program
$149–$249
Compounded Semaglutide

Lemonaid Health

+Broad national telehealth generalist spanning sexual health, weight loss, hair loss, mental health, women's health and primary care under one account.
+Low-friction ED pricing: a single $25 consult covers up to 12 refills, with generic medication priced from $2/pill.
+More than a decade of operating history (founded 2013) with an established patient base and four regional medical groups providing licensed physician coverage.
−Ownership in flux: 23andMe acquired Lemonaid for roughly $400M in 2021, then filed for bankruptcy in 2025 and sold it to nonprofit TTAM Research Institute for approximately $10M — patients have no visibility into whether care continuity, medical staffing, or data handling changed under the new owner.
−Full pricing for most services beyond the advertised ED and GLP-1 offers is not published and only appears after intake.
−Trustpilot reviews cite inconsistent provider conduct, including reports of rude or dismissive clinicians and at least one unexplained prescription refusal for a long-term patient.
Read the full Lemonaid Health review →

Sprout Health

+Offers both compounded (semaglutide, tirzepatide) and branded (Wegovy, Zepbound) GLP-1s alongside NAD+
+Entry pricing ($149/mo semaglutide, $199/mo tirzepatide) is published before intake
+Prescribing runs through MD Integrations, an established white-label physician network
−FDA warning letter (Sept 9, 2025) for marketing compounded GLP-1s as 'FDA-approved'
−BBB rating of F for failing to respond to complaints; multiple reports of patients forced to use chargebacks or stop-payments to cancel
−Recurring complaints of late or missing refills, wrong doses shipped, and no phone support
Read the full Sprout Health review →

Lemonaid Health vs Sprout Health — FAQ

Is Lemonaid Health better than Sprout Health?

▾

Lemonaid Health scores higher overall in our independent evaluation (66.1/100 vs 50.9/100), leading on trust & safety, value, experience, product range, reputation.

Is Lemonaid Health or Sprout Health cheaper?

▾

Lemonaid Health has the lower starting price (from $10/mo vs $149/mo for Sprout Health). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Lemonaid Health and Sprout Health both offer?

▾

Both platforms treat Weight Loss / GLP-1. Lemonaid Health covers 4 treatment categories total and Sprout Health covers 2.

Still deciding?